Zhang Y - Search Results

1

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.

Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, Chen D, Wei J, Ti D, Liu Z, Mei Q, Li X, Dong L, Nie J, Zhang Y, Han W. Wang Y, et al. Among authors: zhang y. Nat Commun. 2021 Jan 18;12(1):409. doi: 10.1038/s41467-020-20696-x. Nat Commun. 2021. PMID: 33462245 Free PMC article.

2

Repair and regeneration of skin injury by transplanting microparticles mixed with Wharton's jelly and MSCs from the human umbilical cord.

Zhang Y, Hao H, Liu J, Fu X, Han W. Zhang Y, et al. Int J Low Extrem Wounds. 2012 Dec;11(4):264-70. doi: 10.1177/1534734612463577. Epub 2012 Oct 21. Int J Low Extrem Wounds. 2012. PMID: 23089966

3

Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy.

Zhang Y, Wang J, Wang Y, Lu XC, Fan H, Liu Y, Zhang Y, Feng KC, Zhang WY, Chen MX, Fu X, Han WD. Zhang Y, et al. Among authors: zhang wy. Clin Dev Immunol. 2013;2013:195691. doi: 10.1155/2013/195691. Epub 2013 Dec 9. Clin Dev Immunol. 2013. PMID: 24382970 Free PMC article. Clinical Trial.

4

Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.

Fan H, Lu X, Wang X, Liu Y, Guo B, Zhang Y, Zhang W, Nie J, Feng K, Chen M, Zhang Y, Wang Y, Shi F, Fu X, Zhu H, Han W. Fan H, et al. Among authors: zhang w, zhang y. J Immunol Res. 2014;2014:371087. doi: 10.1155/2014/371087. Epub 2014 May 21. J Immunol Res. 2014. PMID: 24963497 Free PMC article. Clinical Trial.

5

Analysis of adverse events following the treatment of autologous cytokine-induced killer cells for adoptive immunotherapy in malignant tumour sufferers.

Zhang Y, Xia L, Zhang Y, Wang Y, Lu X, Shi F, Liu Y, Chen M, Feng K, Zhang W, Fu X, Han W. Zhang Y, et al. Among authors: zhang w. Expert Opin Biol Ther. 2015 Apr;15(4):481-93. doi: 10.1517/14712598.2015.988134. Epub 2014 Dec 1. Expert Opin Biol Ther. 2015. PMID: 25435128

6

Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.

Wang Y, Zhang WY, Han QW, Liu Y, Dai HR, Guo YL, Bo J, Fan H, Zhang Y, Zhang YJ, Chen MX, Feng KC, Wang QS, Fu XB, Han WD. Wang Y, et al. Among authors: zhang wy, zhang y, zhang yj. Clin Immunol. 2014 Dec;155(2):160-75. doi: 10.1016/j.clim.2014.10.002. Epub 2014 Oct 16. Clin Immunol. 2014. PMID: 25444722

7

The four-herb Chinese medicine ANBP enhances wound healing and inhibits scar formation via bidirectional regulation of transformation growth factor pathway.

Hou Q, He WJ, Hao HJ, Han QW, Chen L, Dong L, Liu JJ, Li X, Zhang YJ, Ma YZ, Han WD, Fu XB. Hou Q, et al. PLoS One. 2014 Dec 9;9(12):e112274. doi: 10.1371/journal.pone.0112274. eCollection 2014. PLoS One. 2014. PMID: 25489732 Free PMC article.

8

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.

Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, Wang Y, Wang C, Shi F, Zhang Y, Chen M, Feng K, Wang Q, Zhu H, Fu X, Li S, Han W. Dai H, et al. Among authors: zhang w, zhang y. Oncoimmunology. 2015 May 26;4(11):e1027469. doi: 10.1080/2162402X.2015.1027469. eCollection 2015 Nov. Oncoimmunology. 2015. PMID: 26451310 Free PMC article.

9

An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.

Zhang Y, Zhang W, Dai H, Wang Y, Shi F, Wang C, Guo Y, Liu Y, Chen M, Feng K, Zhang Y, Liu C, Yang Q, Li S, Han W. Zhang Y, et al. Among authors: zhang w. Sci China Life Sci. 2016 Apr;59(4):379-85. doi: 10.1007/s11427-016-5035-4. Epub 2016 Mar 24. Sci China Life Sci. 2016. PMID: 27009300

10

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.

Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, Li X, Zhang YJ, Zhang WY, Chen MX, Zhang Y, Feng KC, Liu Y, Li SX, Yang QM, Han WD. Wang CM, et al. Among authors: zhang wy, zhang yj, zhang y. Clin Cancer Res. 2017 Mar 1;23(5):1156-1166. doi: 10.1158/1078-0432.CCR-16-1365. Epub 2016 Aug 31. Clin Cancer Res. 2017. PMID: 27582488 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

238,417 results

Search Page